Publicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (15)

2023

  1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

    Journal of Clinical Virology, Vol. 167

  2. Testing a vaccine candidate against Hepatitis C virus designed by combinatorial optimization

    Scientific Reports, Vol. 13, Núm. 1

2017

  1. Antiretroviral treatment of HIV-2 infection

    Future Virology, Vol. 12, Núm. 8, pp. 461-472

  2. HIV type 2 epidemic in Spain: Challenges and missing opportunities

    AIDS, Vol. 31, Núm. 10, pp. 1353-1364

2012

  1. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial

    Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968

2008

  1. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin

    Journal of Viral Hepatitis, Vol. 15, Núm. 5, pp. 363-369

2007

  1. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients

    Journal of Viral Hepatitis, Vol. 14, Núm. 6, pp. 387-391

  2. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin

    Antiviral Therapy, Vol. 12, Núm. 4, pp. 469-476

  3. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance

    Journal of Antimicrobial Chemotherapy, Vol. 59, Núm. 4, pp. 698-704

  4. Recomendaciones españolas sobre el uso adecuado de enfuvirtida

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. 2, pp. 131-142

  5. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 8, pp. 972-982

2005

  1. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1

    Clinical Infectious Diseases, Vol. 41, Núm. 2, pp. 227-232

  2. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C

    Antiviral Therapy, Vol. 10, Núm. 5, pp. 657-662

  3. Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain

    Clinical Infectious Diseases, Vol. 41, Núm. 9, pp. 1350-1354

2004

  1. Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals

    Journal of Virological Methods, Vol. 121, Núm. 1, pp. 115-118